India’s Maxygen Expects Amgen Patent Suit Over G-CSF Compounds
This article was originally published in PharmAsia News
Indian biotech Maxygen says U.S.-based Amgen's recent acquisition of a patent for its G-CSF class of proteins could mean a legal fight between the two companies. Amgen obtained the patent June 3 for the granulocyte colony stimulating factor, a natural protein important in production of white blood cells. Maxygen's Maxy-G34 belongs to that protein class and has a patent for its compound until 2021. The drug is currently in Phase II trials and the company expects Amgen to sue once the U.S. firm begins selling its own G-CSF compound. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?